Q-omics provides the consensus-scored RNF169 profile across patient tissues and cancer cell-line models. RNF169 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNF169 is differentially expressed in 11, with the highest sampling consensus in CHOL. Additionally, RNF169 RNA expression shows 21,018 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, CHOL, and THYM as cancer lineages where RNF169 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF169 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF169 survival associations across molecular data types. RNF169 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF169 RNA expression–survival associations across cancer types. High RNF169 expression shows unfavorable associations in PAAD and ACC, but favorable associations in KIRC, UCS, HNSC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNF169 RNA expression.
This table summarizes RNF169 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in CHOL for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RNF169. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF169 shows lower tumor expression in THCA and higher tumor expression in CHOL, LUSC, COAD, LIHC and BRCA. The CHOL box plot shows higher RNF169 RNA expression in tumor versus normal tissue (log2 FC = +1.736, t-test p < 0.001).
This table shows molecular features associated with RNF169 in patient tissues and cancer cell lines. In patient samples, RNF169 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF169 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
